2022
Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study
Thompson H, Hogan A, Walker P, Winskill P, Zongo I, Sagara I, Tinto H, Ouedraogo J, Dicko A, Chandramohan D, Greenwood B, Cairns M, Ghani A. Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study. The Lancet Global Health 2022, 10: e1782-e1792. PMID: 36400084, DOI: 10.1016/s2214-109x(22)00416-8.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionSeasonal transmission settingsS vaccinationTransmission settingsTransmission seasonFull therapeutic coursePhase 3b trialSevere malaria outcomesUK Medical Research CouncilEstimates of casesDuration of protectionMalaria transmission intensityEntomological inoculation rateGreater absolute reductionMedical Research CouncilTransmission intensitySignificant additional protectionAge-based strategiesMalaria outcomesClinical malariaMalaria chemopreventionVaccination scheduleMalaria vaccineClinical incidenceClinical trials
2020
The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data
Bretscher M, Dahal P, Griffin J, Stepniewska K, Bassat Q, Baudin E, D’Alessandro U, Djimde A, Dorsey G, Espié E, Fofana B, González R, Juma E, Karema C, Lasry E, Lell B, Lima N, Menéndez C, Mombo-Ngoma G, Moreira C, Nikiema F, Ouédraogo J, Staedke S, Tinto H, Valea I, Yeka A, Ghani A, Guerin P, Okell L. The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data. BMC Medicine 2020, 18: 47. PMID: 32098634, PMCID: PMC7043031, DOI: 10.1186/s12916-020-1494-3.Peer-Reviewed Original ResearchConceptsFirst-line treatmentDuration of chemoprophylaxisPost-treatment prophylaxisIndividual patient dataAS-AQArtemether-lumefantrinePlasmodium falciparum malaria casesPfcrt 76TPatient dataFalciparum malaria casesPotential public health impactHigh transmission areasDuration of protectionLonger protectionPublic health impactTransmission intensityWild-type Pfmdr1Pfmdr1 86YMalaria morbidityClinical incidenceMean durationClinical trialsChemoprevention programMultivariable modelHigh prevalence